The New Peptide Compounding Policy: What It Means for Fort Collins Patients

HHS stated that it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound a drug from one of six peptide bulk substances:

• BPC-157
• TB-500
• KPV
• MOTS-c
• Semax
• Epitalon

Until this policy, pharmacies had no clear basis to compound these peptides: they aren't ingredients of any FDA-approved drug and they aren't on the FDA's list of permitted bulk substances. That is why clinics could not prescribe them through a licensed pharmacy, and why most of what sold online came from unregulated sources.

The policy attaches conditions. A prescription must be written for a specific patient. Each compounded product may contain only one of the six peptides, in the forms the policy lists for it; a product that combines two of them is not covered. The raw ingredient must come from a manufacturer registered with the FDA and must carry a laboratory certificate of analysis. The pharmacy must test what it makes and must report serious side effects. HHS's stated reason for the conditions is that patients already buying these peptides from unregulated sellers would have a more controlled option.

It does not approve anything. An HHS spokesperson said the policy “does not grant FDA approval or establish clinical safety and effectiveness.” Compounded peptides prepared under it are compounded drugs: not FDA-approved, not reviewed by the FDA for safety, effectiveness or quality before they are sold. That is true of every compounded medication, from every pharmacy, prescribed by every clinic, including Peak Medical Wellness.

It is also not a final rule. It was filed as a draft with a public comment period from October 30 through November 13, 2026, and it remains in effect only until the FDA finalizes a rule on compounded peptides, which the FDA has not yet proposed. Enforcement discretion means the government is choosing not to act; HHS says it can revisit that choice if a safety or quality problem appears.

On July 23 and 24, 2026, an FDA advisory committee on pharmacy compounding voted to recommend adding these six peptides to the list of substances pharmacies may use, by margins as narrow as 8 to 6. The committee rejected a seventh. The FDA's own scientific reviewers had recommended against every one of them, saying the safety and effectiveness information was insufficient and raising concerns about inconsistent batches and immune reactions. A committee vote is a recommendation, not approval; the FDA keeps the final say and has not completed its rulemaking. The October policy came from HHS leadership citing that committee vote.

Separately, in spring 2026 the FDA took GHK-Cu, a copper peptide, off its list of substances that may pose significant safety risks and placed it among the substances under evaluation that pharmacies may compound under an existing interim policy; the advisory committee is due to review it by early 2027. GHK-Cu was already offered at Peak Medical Wellness on that basis.

The honest summary is that these peptides have been studied far more in animals and cells than in people.

• BPC-157 is a synthetic peptide modeled on a fragment of a protein found in the stomach. Nearly all published research is in animal models of tendon, ligament, muscle and gut injury. Human data are limited to a few very small studies.
• TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in cell movement and tissue repair. The full protein has been studied in early human trials for other uses; the shorter fragment sold as TB-500 has mostly animal data.
• KPV is a three-amino-acid fragment of a naturally occurring hormone, studied in cell and animal models of inflammation, particularly in the gut. There are no human efficacy trials.
• MOTS-c is a small peptide encoded in mitochondrial DNA, studied in animals for metabolism, insulin sensitivity and exercise capacity. Human data are limited to small early studies.
• Semax is a short synthetic peptide related to a fragment of a naturally occurring hormone, developed and studied mainly in Russia for cognition and recovery after stroke; there is little independent Western research. Epitalon is a four-amino-acid synthetic peptide studied mostly in Russian research on aging; human data are sparse. Both are covered by the policy. Peak Medical Wellness does not currently offer either.

The pairing of BPC-157 and TB-500 is widely sold under the nickname “Wolverine shot.” It is a nickname, not a description of what the pairing does, and the combination has not been studied in human trials. The policy also covers each peptide only as its own single-ingredient product, so a licensed pharmacy would prepare the two separately. Our BPC-157 and TB-500 guide goes deeper on both.

None of these has an FDA-approved product behind it. No regulator has set a dose, a duration, or a monitoring standard. When a clinic prescribes one, the provider is working from limited evidence, clinical judgment and the patient's own history, and should say so.

Peak Medical Wellness plans to offer BPC-157, TB-500 (including the pairing known as the “Wolverine shot,” prescribed as two separate compounded medications), KPV and MOTS-c by prescription. Each one goes through our clinical review and procedure process first, and our compounding pharmacy partner has to be supplying it under the policy's sourcing and testing conditions. If you're interested, the right first step is the same as for any treatment here: an in-person visit with a provider who reviews your history and goals, orders any labs that matter, and tells you plainly what is known, what isn't, and whether a peptide fits you at all. Book that visit now and we'll tell you where availability stands.

Either way, two things won't change at Peak Medical Wellness. We don't sell peptides from a website or a questionnaire, and we don't describe compounded peptides as approved, proven or risk-free, because they aren't.

Peptides are one part of what we do. Our peptide therapy page lists what is offered today, our beginner's guide covers the basics, and our patient safety page explains how we choose pharmacies. If the compounded GLP-1 news is what brought you here, that guide covers the FDA's warning letters.

Products sold as “research use only” or shipped from unregulated sellers are not made for human use, and there is no one checking what's in the vial. A recent news investigation sent a peptide bought from an unregulated seller to a laboratory and found no peptide in it at all. If you have been buying peptides online, bring what you have to your visit; a provider would rather see it than guess.

1. Is this peptide FDA-approved, or compounded? (For these six, the answer is compounded.)
2. Which licensed pharmacy prepares it, and does that pharmacy meet the policy's sourcing and testing conditions?
3. What does the evidence in humans actually show for the reason I'm considering it?
4. What are the known side effects, and what's unknown?
5. Who follows my care, and how do I reach them if something goes wrong?
6. What happens if the policy changes or the pharmacy stops supplying it?